Fintel reports that on April 10, 2023, JP Morgan maintained coverage of BioNTech SE (NASDAQ:BNTX) with a Neutral recommendation.
Analyst Price Forecast Suggests 52.89% Upside
As of April 7, 2023, the average one-year price target for BioNTech SE is $195.26. The forecasts range from a low of $141.27 to a high of $273.00. The average price target represents an increase of 52.89% from its latest reported closing price of $127.71.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for BioNTech SE is $9,869MM, a decrease of 42.99%. The projected annual non-GAAP EPS is $17.32.
What are Other Shareholders Doing?
Bartlett & Co. holds 1K shares representing 0.00% ownership of the company. No change in the last quarter.
SOA Wealth Advisors, LLC. holds 0K shares representing 0.00% ownership of the company. No change in the last quarter.
Eagle Bay Advisors holds 0K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 0K shares, representing a decrease of 12.22%. The firm decreased its portfolio allocation in BNTX by 99.91% over the last quarter.
BlackRock Health Sciences Trust II holds 62K shares representing 0.03% ownership of the company.
DLHAX - Delaware Healthcare Fund holds 20K shares representing 0.01% ownership of the company.
What is the Fund Sentiment?
There are 429 funds or institutions reporting positions in BioNTech SE.
This is an increase
of
50
owner(s) or 13.19% in the last quarter.
Average portfolio weight of all funds dedicated to BNTX is 0.35%,
a decrease
of 11.48%.
Total shares owned by institutions increased
in the last three months by 6.43% to 46,735K shares.
The put/call ratio of BNTX is 1.66, indicating a
bearish
outlook.
BioNTech SE Background Information
(This description is provided by the company.)
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
See all BioNTech SE regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
